Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries


  • A full access package includes WHO policy guidance on the use of antigen-based rapid diagnostic tests, manufacturer volume guarantees for low and middle-income countries,  catalytic funding to assist governments to deploy the tests and an initial US$50 million procurement fund
  • Several rapid, point-of-care antigen tests are being assessed by WHO for Emergency Use Listing (EUL)
  • Agreements between the Bill & Melinda Gates Foundation and test manufacturers Abbott and SD Biosensor make available innovative tests priced at a maximum of US$5 for low- and middle-income countries (LMICs)
  • The Global…



Source link

Tags:
ACM
About Author: ACM
This information is 3rd party content that is added to ACM strictly for non-commercial informational purposes. Information is the Key to Set the Black Mind Free